Navigation Links
R&D Trends: Depression - Clinical attrition driven by mature market conditions
Date:3/22/2012

opular approaches include glutamate and neuropeptide receptor modulation. Datamonitor sees the future of treatment in depression as the specific targeting of treatment-resistant patients.Clinical trial design in depression is largely standardized. Although not required, head-to-head trials may allow for a more favorable label and explicit marketing claims. Datamonitor believes that future trials will be designed for regulatory approval in patients with treatment-resistant depression, or for use as an add-on to existing therapies.What are the key trends in the depression pipeline?What is the clinical gold standard and how do new candidates have to compare to this to successfully penetrate the market?How will new antidepressant treatments evolve in the next 20 years?

 

 

 

OVERVIEW

Catalyst

Summary

EXECUTIVE SUMMARY

Strategic scoping and focus

Update details: January 2012

Datamonitor key findings

Related reports

CLINICAL PIPELINE OVERVIEW

Overview of the depression pipeline

Datamonitor has identified 46 separate programs in clinical development

Emerging features of the depression pipeline

Changes in pipeline dynamics

Companies involved in the depression pipeline

Discontinued pipeline drugs in depression

54 distinct depression projects have been discontinued since 2010

The vast majority of discontinuations happen either during preclinical testing or Phase II studies

Neuropeptide modulators and monoamine reuptake inhibitors head the list of discontinued projects

TARGET PRODUCT PROFILE

Comparator therapies

Lexapro (escitalopram; Forest/Lundbeck)

Target product profile versus current level of attainment

CLINICAL TRIAL DESIGN IN DEPRESSION

Clinical trials

Commonly used clinical trial endpoints for depression

Typical trial design

Trial length is commonl
'/>"/>

SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Delcath Systems, Inc. Appoints Dr. Krishna Kandarpa its Executive Vice President R&D and Chief Medical Officer
2. LOREAL and Hurel Corporation Announce R&D Collaboration to Develop a Non-Animal Alternative, Microfluidic Biochip
3. Micromet Highlights Clinical Plans and Regulatory Strategy for Lead Product Candidate Blinatumomab at its Annual R&D Day
4. R&D Investment by U.S. Biopharmaceutical Companies Remains Strong Despite Ongoing Economic Challenges
5. R&D Investment by U.S. Biopharmaceutical Companies Increases to Record $65.3 Billion, Study Finds
6. Kendle Director of Global Safety and Pharmacovigilance, Drew Kilpatrick, PhD, Named One of Ten Notable People in R&D
7. Gelesis Unveils Novel Non-Invasive Capsulated Device for Obesity and Presents Clinical Data; Appoints Former Pfizer R&D President to Board
8. NeoStem, Inc. Officially Launches Adult Stem Cell Collection Center and R&D Laboratory in Cambridge, Massachusetts
9. Global Pharmaceutical R&D Productivity Declining According to Thomson Reuters, CMR International
10. Pfizer Inc and GoIndustry DoveBid Partner to Auction Surplus Equipment from R&D Facilities Across the United States
11. Orthocare Innovations Receives Prestigious R&D 100 Award for Novel Web-Based Rehabilitation Outcomes Assessment System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... , July 6, 2015  Impax Laboratories, Inc. ... will release its second quarter 2015 financial results on ... the U.S. financial markets. The Company will host a ... at 8:30 a.m., Eastern Time on August 10, 2015. ... be accessible through the Investor Relations section of the ...
(Date:7/6/2015)... 2015 Mauna Kea Technologies ... confocal laser endomicroscopy platform, announced today it has ... Ministry of Health, Labor and Welfare (MHLW) for ... AQ-Flex 19 miniprobe.   Used during ... is comprised of a fiber-optic microscope that is ...
(Date:7/6/2015)...  Protiviti, a global consulting firm, today announced the ... World publication ( www.protiviti.com/iaworld ). For more than ... evolution of the internal audit profession through the eyes ... means to providing senior executives and internal audit professionals ... The 2015 edition of Internal Auditing ...
Breaking Medicine Technology:Impax to Report Second Quarter 2015 Results on August 10, 2015 2Mauna Kea Technologies Receives Regulatory Approval for the AQ-Flex 19 Miniprobe in Japan 2Mauna Kea Technologies Receives Regulatory Approval for the AQ-Flex 19 Miniprobe in Japan 3New Edition of Internal Auditing Around the World from Protiviti Explores Changes and Trends 2
... Data Presented Today at ACG Annual Scientific Meeting ... Inc. (formerly Microbia, Inc.) and Forest Laboratories,Inc. (NYSE: ... results from a Phase,2b study assessing linaclotide,s safety ... with constipation (IBS-C). Analysis of the data,indicates that ...
... DIEGO, Oct. 7 Ardea Biosciences, Inc.,(Nasdaq: ... "RDEA119, a Potent,and Highly Selective MEK1/2 Inhibitor is ... Colitis in Mice," was presented at the,American College ... The poster, which provided data from a preclinical ...
Cached Medicine Technology:Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 2Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 3Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 4Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 5Ardea Biosciences Presents Preclinical Anti-Inflammatory Data on its Lead MEK Inhibitor, RDEA119, at the ACG 2008 Annual Meeting 2Ardea Biosciences Presents Preclinical Anti-Inflammatory Data on its Lead MEK Inhibitor, RDEA119, at the ACG 2008 Annual Meeting 3Ardea Biosciences Presents Preclinical Anti-Inflammatory Data on its Lead MEK Inhibitor, RDEA119, at the ACG 2008 Annual Meeting 4
(Date:7/7/2015)... ... July 07, 2015 , ... At the end of June Pacific Prime Renewals team ... green’ . This initiative, spearheaded by the Renewals Manager, Danielle Cotton, aims to not only ... , On this initiative Cotton explained, “We send anything between 300 and 600 pieces of ...
(Date:7/7/2015)... ... July 07, 2015 , ... On Saturday, May 16th, 2015, ... the Manistee Golf and Country Club. Best Drug Rehabilitation staff members were delighted to ... helping underprivileged children. Kiwanis International, the parent of the Manistee Kiwanis Club, is a ...
(Date:7/7/2015)... ... July 07, 2015 , ... With a new community program in the ... Angels and announced a new charity campaign to raise funds in support of programs ... Angels, which was created especially to care for the special needs of our soldiers. ...
(Date:7/7/2015)... PA (PRWEB) , ... July 07, 2015 , ... ... financial executive Ellen Purdy as the company’s new Chief Financial Officer, effective July ... and leadership experience in companies ranging from a multi-billion dollar, global chemical company ...
(Date:7/7/2015)... ... July 07, 2015 , ... Nationally-renowned attorneys ... their new website, the Invokana Ketoacidosis Lawsuit Center . The website provides ... a resource for persons wishing to learn more about Invokana lawsuits for kidney ...
Breaking Medicine News(10 mins):Health News:Pacific Prime Hong Kong Renewals Team Starts Push to go Green 2Health News:Best Drug Rehabilitation Team Participates in Kiwanis Club Golf Outing Fundraiser 2Health News:Clear Insurance Group and Nonprofit Soldiers’ Angels Initiate New Charity Campaign in San Antonio, TX to Provide Aid and Comfort for Veterans 2Health News:Clear Insurance Group and Nonprofit Soldiers’ Angels Initiate New Charity Campaign in San Antonio, TX to Provide Aid and Comfort for Veterans 3Health News:Office Practicum Announces new CFO 2Health News:National Attorneys Launch Invokana Ketoacidosis Lawsuit Center 2Health News:National Attorneys Launch Invokana Ketoacidosis Lawsuit Center 3
... artery disease live longer if they receive coronary artery ... artery-opening angioplasty or heart medications, according to a Duke ... 40 percent of patients diagnosed with severe coronary disease ... given the opportunity to receive bypass surgery, the researchers ...
... Montreal: A new study has found that brains of ... of white matter. // The study, available in the current ... researchers from the Université de Montréal, the Montreal Neurological Institute ... congenital amusia) is known to last a lifetime which impedes ...
... one in every 523 children and adolescents in the ... estimates // from a major national study called SEARCH ... surveillance effort of diabetes among youth under the age ... Ronny A. Bell, Ph.D., M.S., associate professor of epidemiology ...
... Osteoarthritis, the degenerative inflammatory bone disease, may be a sign ... print in the Annals of the Rheumatic Diseases. ,The ... people, aged between 30 and 79. Most of them were ... of all participants to check for signs of osteoarthritis and ...
... little-known antibiotic shows early promise as an anti-cancer agent, ... human tumors, // according to researchers at the University ... findings appear in the Oct. 1 issue of Cancer ... believed to be over-expressed in cancer cells to screen ...
... spleen injuries better than non-contrast enhanced sonography, according ... of California, Davis School of Medicine department of ... included 22 liver, spleen or renal injuries. Contrast-enhanced ... while non-contrast-enhanced sonography revealed 11 (50%). ,“The ...
Cached Medicine News:Health News:Bypass Surgery, a Better Option than Angioplasty for Severe Heart Patients 2Health News:Bypass Surgery, a Better Option than Angioplasty for Severe Heart Patients 3Health News:Understanding Reasons for Tone deafness 2Health News:One in 523 Children and Adolescents Have Diabetes 2Health News:One in 523 Children and Adolescents Have Diabetes 3Health News:Osteoarthritis May be Sign of Faster “Biological Ageing 2Health News:Antibiotic Inhibits Cancer Gene Activity 2
... EMR addresses the vast information needs of ... clinically-defined templates for common orthopedics complaints, history ... The system also includes orthopedics specific ICD ... capture accurate charges and quickly generate electronic ...
... is a multi-site, implantable biventricular ... and two ventricular ports for ... (AF) who have undergone an ... have NYHA Class II or ...
Achieving Topical Hemostasis After Catheterization Does Not Have to Be Complicated or Costly. Clo-Sur P.A.D. is intended for topical use in the local management of bleeding wounds, such as vascular ...
... XL 10F Percutaneous Vascular Surgical (PVS) System consists ... a Perclose Knot Pusher. The Prostar XL 10F ... contains two pairs of sutured needles as well ... which precisely control the needles during deployment. the ...
Medicine Products: